Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.22 EUR | +0.10% | +0.29% | +34.54% |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
May. 03 | AIB buys back EUR999 million worth of shares from Irish government | AN |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company's share price in relation to its net book value makes it look relatively cheap.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Banks
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+34.54% | 13.7B | B+ | ||
+19.12% | 582B | C+ | ||
+18.87% | 313B | C+ | ||
+15.71% | 251B | C+ | ||
+21.74% | 209B | C | ||
+19.14% | 180B | B- | ||
+24.16% | 169B | B- | ||
+9.58% | 164B | C+ | ||
+11.18% | 154B | B- | ||
-10.40% | 140B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A5G Stock
- Ratings AIB Group plc